Effects of cerivastatin and parathyroid hormone on the lumbar vertebra of aging male Sprague-Dawley rats

Bone

Volumn 31, Issue 1, 2002, Pages 173-179

  Banu, J ^a   Kalu, D N ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Cerivastatin; Lumbar vertebra; Male Sprague Dawley (SD) rats; Parathyroid hormone (PTH)

Indexed keywords

CERIVASTATIN; HIGH DENSITY LIPOPROTEIN; PARATHYROID HORMONE[1-34]; TRIACYLGLYCEROL;

ADIPOSE TISSUE; AGING; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BONE ATROPHY; BONE DENSITY; BONE MINERAL; CANCELLOUS BONE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOSE RESPONSE; LIPID BLOOD LEVEL; LUMBAR VERTEBRA; MALE; MUSCLE MASS; NONHUMAN; RAT;

EID: 0036309480     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(02)00803-7     Document Type: Article

References (39)

1. Analysis of the effects of growth hormone, exercise and food restriction on cancellous bone in different bone sites in middle-aged female rats
2. Separate and combined effects of growth hormone and parathyroid hormone on cortical bone osteopenia in ovariectomized aged rats
3. Cerivastatin: Pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor
4. No clinically relevant effect of fluvastatin on postmenopausal bone remodeling
5. Hypertriglyceridemia: A review of clinical relevance and treatment options: Focus on cerivastatin
6. Statin use and bone mineral density (BMD) in older women: The Women's Health Initiative observational study (WHI-OS)
7. Hypocholesterolemic effects of 3-hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) reductase inhibitors in the guinea pig
8. Incidence of clinically diagnosed vertebral fractures: A population based study in Rochester, Minnesota
9. Anabolic actions of parathyroid hormone on bone
10. Human parathyroid hormone (1-34) increases bone formation and strength of cortical bone in aged rats
11. Human parathyroid hormone (1-34) and (1-84) increase the mechanical strength and thickness of cortical bone in rats
12. Withdrawal of parathyroid hormone treatment causes rapid resorption of newly formed vertebral cancellous and endocortical bone in old rats
13. Cerivastatin increases BMP-2 expression in vivo and bone formation in concentrations two orders of magnitude lower than other statins
14. Fluvastatin and cerivastatin are not anabolic for bone after local or systemic administration of non-toxic doses in mice and rats
15. Osteoporosis
16. Anabolic actions of parathyroid hormone in the skeleton of animals
17. Effect of treatment for 6 months with human parathyroid hormone (1-34) peptide in ovariectomized cynomolgus monkeys (Macaca fascicularis)
18. Animal models of the aging skeleton
19. Aging and dietary modulation of rat skeleton and parathyroid hormone
20. The Type I/type II model for involutional osteoporosis
21. Trabecular bone microarchitecture, bone mineral density, and vertebral fractures in male osteoporosis
22. Human parathyroid hormone-(1-34) prevents bone loss and augments bone formation in sexually mature ovariectomized rats
23. The anabolic effect of parathyroid hormone on cortical bone mass, dimensions and strength assessed in a sexually mature, ovariectomized rat model
24. The anabolic effects of human parathyroid hormone (hPTH) on rat vertebral body mass are also reflected in the quality of bone, assessed by biomechanical testing: A comparison study between hPTH-(1-34) and hPTH-(1-84)
25. Statins and their potential for osteoporosis
26. Stimulation of bone formation in vitro and in rodents by statins
27. Statin Given perorally to adult rats increases cancellous bone mass and compressive strength
28. Parathyroid hormone (1-34) and (1-84) stimulate cortical bone formation both from periosteum and endosteum
29. Effect of pravastatin on fracture incidence in the lipid study: A randomized controlled trial
30. Involutional osteoporosis
31. The structural basis of bone fragility in men
32. Cerivastatin, a new potent synthetic HMG-CoA reductase inhibitor: Effect of 0.2 mg daily in subjects with primary hypercholesterolemia
33. Use of statins and risk of fractures
34. Preclinical safety evaluation of cerivastatin, a novel HMG-CoA reductase inhibitor
35. Male rodent model of aging bone loss in men
36. Cerivastatin increases cortical bone formation in OVX rats
37. Anabolic effects of parathyroid hormone on cortical bone in ovariectomized rats